(P 333) Recombinant Erythropoietin Application in Complex Therapy of Chronic Heart Failure (CHF)

• Published in: Tissue engineering. Part A 2008-05, Vol.14 (5), p.903-903
• Main Authors: Perepelyuk, M, Kholodkova, O, Pykhtyeyev, D
• Format: Article
• Language: English
• ISSN: 1937-3341; 1937-335X

Background: CHF becomes widespread syndrome in many patients. It is related with the ageing and rise of the morbidity of cardio-vascular system among this category of people. Modern methods of CHF treatment doesn't ensure the clinical success in all cases, often are contradictive because of the accompanied pathology. Materials and methods: We used recombinant erythropoietin-8 in complex therapy of CHF II-III functional class under NYHA in 17 males, average age 71 plus or minus 3,2. The cause of CHF in all patients was integration of IHD and hypertonic disease; all the patients conducted myocardium infarction more than 6 months before the research. Seven patients suffered from the constant form of atria fibrillation. Basic therapy of CHF included 8-adrenal blockers, ACE inhibitors, desaggregants, diuretics and anticoagulants instead of desaggregants if necessary. Nine patients additionally got recombinant erythropoietin-8 in the dose of 2000 IU twice with an interval of 2 days. Laboratory and instrumental tests were done before the research and 2 weeks after first injection of erythropoietin. Results: in patients after erythropoietin treatment no arterial pressure rise was observed. Clinical data were approximately similar to those in the group without erythropoietin treatment. No positive dynamic of creatinin and transaminases of blood were investigated. The decrease of the level of Na-uretic peptide (22,8 % lower) and improvement of global (systolic-diastolic) function of the left ventricle under results by Tei-index (24,1 % decrease) were found. Conclusions: the obtained data demonstrate safety and effectiveness of recombinant erythropoietin- beta in complex therapy of CHF of ischemic genesis in aged males.